{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T12:00:17Z","timestamp":1768219217844,"version":"3.49.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["LH202402007"],"award-info":[{"award-number":["LH202402007"]}],"id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016350","name":"Sichuan Provincial Administration of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2023MS002"],"award-info":[{"award-number":["2023MS002"]}],"id":[{"id":"10.13039\/501100016350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioid-induced constipation (OIC) is a common and serious side effect of long-term opioid analgesic therapy. As traditional laxatives often show limited efficacy, it is crucial to explore treatment strategies that effectively relieve constipation without compromising analgesic effects. In response to this clinical need, Opioid-receptor antagonists have been approved for OIC. Although new evidence has emerged in recent years, a comprehensive analysis of efficacy outcomes (such as constipation symptoms, quality of life, and satisfaction) is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To summarise and analyze evidence on the efficacy and safety of opioid-receptor antagonists in treating patients with OIC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic search of randomized controlled trials (RCTs) was conducted in PubMed, Embase, Web of Science, and the Cochrane Library up to 11 September 2025. A meta-analysis was carried out using RevMan and Stata, and the GRADE method was employed to evaluate the quality of evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 20 studies (22 RCTs) involving 7,761 patients were included. Opioid-receptor antagonists significantly increased the change in spontaneous bowel movement (WMD = 1.10, 95% CI: 0.74\u20131.46); improved the proportion of responders (RR = 1.48, 95% CI: 1.28\u20131.70); enhanced quality of life (WMD = \u22120.20, 95% CI: \u22120.28 to \u22120.12) and treatment satisfaction (WMD = \u22120.32, 95% CI: \u22120.54 to \u22120.10). The patient assessment of constipation symptoms questionnaire showed a minor tendency of improvement (WMD = \u22120.16, 95% CI: \u22120.31 to 0.00). The incidence of serious adverse events indicates that no statistically significant difference was observed between treatment and placebo (RR = 0.88, 95% CI: 0.74\u20131.05). The incidence of other adverse events was higher in the treatment group than in the placebo group (RR = 1.22, 95% CI: 1.08\u20131.38).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Opioid-receptor antagonists are effective in treating patients with OIC. The risk of serious adverse events did not change statistically. The incidence of adverse events appears to increase with longer treatment duration, although this observation seems to require further validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>CRD420251154280.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1749875","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:04Z","timestamp":1768196584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of opioid-receptor antagonists for opioid-induced constipation: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuanlin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyuan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Defu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiren","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zugang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangchun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1007\/s11845-024-03652-2","article-title":"Effect of oral naloxone on opioid-induced constipation in methadone maintenance treatment patients, a double-blind, placebo-control, clinical trial","volume":"193","author":"Akhgarandouz","year":"2024","journal-title":"Ir. J. Med. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/0006-8993(90)91336-f","article-title":"The bidirectional dose-dependent effect of systemic naloxone is also related to the intensity and duration of pain-related disorders: a study in a rat model of peripheral mononeuropathy","volume":"525","author":"Attal","year":"1990","journal-title":"Brain Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1124\/mol.113.088096","article-title":"Caged naloxone reveals opioid signaling deactivation kinetics","volume":"84","author":"Banghart","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1037\/pha0000723","article-title":"Pain and withdrawal are common among patients receiving medications for opioid use disorder and associated with pain catastrophizing, negative affect, and poor sleep","volume":"32","author":"Berry","year":"2024","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2147\/jpr.S282738","article-title":"Naldemedine improves patient-reported outcomes of opioid-induced constipation in patients with chronic non-cancer pain in the COMPOSE phase 3 studies","volume":"14","author":"Camilleri","year":"2021","journal-title":"J. Pain Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2147\/JPR.S417045","article-title":"Efficacy and safety of naloxegol in patients with chronic non-cancer pain who experience opioid-induced constipation: a pooled analysis of two global, randomized controlled studies","volume":"16","author":"Chey","year":"2023","journal-title":"J. Pain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"174132","DOI":"10.1016\/j.ejphar.2021.174132","article-title":"Pharmacological characterization of naloxegol: in vitro and in vivo studies","volume":"903","author":"Costanzini","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1053\/j.gastro.2018.10.044","article-title":"Opioid-induced constipation (OIC) guideline","volume":"156","author":"Crockett","year":"","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American gastroenterological Association Institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1007\/s12325-021-01766-y","article-title":"Management of opioid-induced constipation and bowel dysfunction: expert opinion of an Italian multidisciplinary panel","volume":"38","author":"De Giorgio","year":"2021","journal-title":"Adv. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-Functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/pm\/pnw240","article-title":"Laxatives do not improve symptoms of opioid-induced constipation: results of a patient Survey","volume":"18","author":"Emmanuel","year":"2017","journal-title":"Pain Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: european expert consensus statement","volume":"7","author":"Farmer","year":"2019","journal-title":"United Eur. Gastroenterology J."},{"key":"B16","unstructured":"Package insert of oral RELISTOR\n          \n          \n          2018"},{"key":"B17","unstructured":"Package insert of MOVANTIK\n          \n          \n          2020"},{"key":"B18","unstructured":"Package insert of SYMPROIC\n          \n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ajgsup.2014.5","article-title":"Molecular physiology of enteric opioid receptors","volume":"2","author":"Galligan","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jcrc.2014.04.005","article-title":"Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit","volume":"29","author":"Gibson","year":"2014","journal-title":"J. Crit. Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the journal of clinical epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"Hale","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract","volume":"155","author":"Holzer","year":"2009","journal-title":"Regul. Pept."},{"key":"B24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpain.2010.06.013","article-title":"A randomized, placebo-controlled phase 3 trial (study SB-767905\/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Irving","year":"2011","journal-title":"J. Pain"},{"key":"B25","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jpain.2010.06.012","article-title":"A randomized, placebo-controlled phase 3 trial (Study SB-767905\/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain","volume":"12","author":"Jansen","year":"2011","journal-title":"J. Pain"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/jco.2016.70.8453","article-title":"Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami","year":"","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/jco.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"102704","DOI":"10.1016\/j.ctrv.2024.102704","article-title":"Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: a systematic review and meta-analysis","volume":"125","author":"Kistemaker","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.14309\/ajg.0000000000002887","article-title":"Opioids and the gastrointestinal tract: the role of peripherally active \u00c2\u00b5-Opioid receptor antagonists in modulating intestinal permeability","volume":"119","author":"Lacy","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s12325-010-0063-0","article-title":"The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review","volume":"27","author":"Leppert","year":"2010","journal-title":"Adv. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/mcg.0000000000002185","article-title":"Treatment of opioid-induced constipation: inducing laxation and understanding the risk of gastrointestinal perforation","volume":"59","author":"Mehta","year":"2025","journal-title":"J. Clin. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","article-title":"A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation","volume":"13","author":"Meissner","year":"2009","journal-title":"Eur. J. Pain"},{"key":"B34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpain.2010.11.008","article-title":"Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study","volume":"12","author":"Michna","year":"2011","journal-title":"J. Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/jgh.14586","article-title":"Peripherally acting \u03bc-opioid antagonist for the treatment of opioid-induced constipation: systematic review and meta-analysis","volume":"34","author":"Nishie","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1093\/pm\/pnaa152","article-title":"Efficacy and safety of peripherally acting Mu-Opioid receptor antagonists for the treatment of opioid-induced constipation: a bayesian network meta-analysis","volume":"21","author":"Ouyang","year":"2020","journal-title":"Pain Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jpain.2004.12.001","article-title":"Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial","volume":"6","author":"Paulson","year":"2005","journal-title":"J. Pain"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2147\/dddt.S221278","article-title":"The use of peripheral \u03bc-Opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety","volume":"14","author":"Pergolizzi","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1001\/jama.2019.15852","article-title":"Medical management of opioid-induced constipation","volume":"322","author":"Rao","year":"2019","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/papr.12535","article-title":"Randomized, double-blind trial of oral methylnaltrexone for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"17","author":"Rauck","year":"2017","journal-title":"Pain Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e16201","DOI":"10.7759\/cureus.16201","article-title":"Efficacy and safety of peripherally acting \u03bc-Opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review","volume":"13","author":"Rekatsina","year":"2021","journal-title":"Cureus"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/pme.12775","article-title":"New formulation of sustained release naloxone can reverse opioid induced constipation without compromising the desired opioid effects","volume":"16","author":"Sanders","year":"2015","journal-title":"Pain Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"546","DOI":"10.17235\/reed.2024.10242\/2024","article-title":"Review document of the Spanish association of neurogastroenterology and motility on the management of opioid-induced constipation","volume":"116","author":"Serra","year":"2024","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"B46","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/JPR.S366460","article-title":"Subcutaneous methylnaltrexone as treatment for opioid-induced constipation in patients with advanced cancer and noncancer illnesses: a post hoc analysis of two clinical trials","volume":"16","author":"Shah","year":"2023","journal-title":"J. Pain Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/17512433.2019.1570845","article-title":"A meta-analysis of naldemedine for the treatment of opioid-induced constipation","volume":"12","author":"Song","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/026921639601000208","article-title":"An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer","volume":"10","author":"Sykes","year":"1996","journal-title":"Palliat. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s002210050330","article-title":"Involvement of the locus coeruleus in analgesic effects of a low dose of naloxone during the inflammatory process","volume":"119","author":"Tsuruoka","year":"1998","journal-title":"Exp. Brain Res."},{"key":"B50","unstructured":"Methylnaltrexone in patients with opioid-induced bowel dysfunction\n          \n          \n          2003"},{"key":"B51","unstructured":"Naloxone SR capsules in patients with opioid induced constipation"},{"key":"B52","unstructured":"Study evaluating the efficacy and safety of subcutaneous methylnaltrexone (MOA-728) for the treatment of opioid-induced-constipation"},{"key":"B53","unstructured":"Evaluation of the efficacy and safety of ADL5945 for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic noncancer pain\n          \n          \n          2010"},{"key":"B54","unstructured":"Evaluation of the efficacy and safety of ADL5945 once daily for the treatment of opioid-induced constipation in adults taking opioid therapy for chronic noncancer pain"},{"key":"B55","unstructured":"A study of oral methylnaltrexone (MNTX) for the treatment of opioid-induced constipation (OIC) in participants with chronic, non-malignant pain"},{"key":"B56","unstructured":"U.S. National Library of medicine. A 12-week extension of the phase III study (D3820C00004) to assess the effect and safety of NKTR-118 in patients with non-cancer-related pain and opioid-induced constipation"},{"key":"B57","unstructured":"Safety study of CB-5945 for the treatment of opioid-induced constipation"},{"key":"B58","unstructured":"ALK37-007: evaluation of safety and efficacy of ALKS 37 (RDC-1036) in adults with opioid-induced constipation (OIC)"},{"key":"B59","unstructured":"ALK37-005: a study of ALKS 37 (RDC-1036) in adults with opioid-induced constipation (OIC)"},{"key":"B60","year":"2017","journal-title":"Targin Non-cancer Pain"},{"key":"B61","unstructured":"Naloxone HCl PR tablets in patients with opioid induced constipation (Naxos)\n          \n          \n          2019"},{"key":"B62","unstructured":"The effect of naldemedine on opioid-induced bowel dysfunction\n          \n          \n          2024"},{"key":"B63","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.3390\/jcm13226689","article-title":"Improving diagnosis and management of Opioid-induced constipation (OIC) in clinical practice: an Italian expert opinion","volume":"13","author":"Varrassi","year":"2024","journal-title":"J. Clin. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.pain.2007.11.008","article-title":"Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain","volume":"137","author":"Webster","year":"2008","journal-title":"Pain"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.pain.2013.04.024","article-title":"A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation","volume":"154","author":"Webster","year":"2013","journal-title":"Pain"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.3748\/wjg.14.4569","article-title":"Diagnosis and treatment of spontaneous colonic perforation: analysis of 10 cases","volume":"14","author":"Yang","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40780-024-00371-9","article-title":"Naldemedine-induced perforation of a diverticulum in the sigmoid colon of a patient with opioid-related constipation: a case report","volume":"10","author":"Yokota","year":"2024","journal-title":"J. Pharm. Health Care Sci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1749875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:43:07Z","timestamp":1768196587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1749875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":68,"alternative-id":["10.3389\/fphar.2025.1749875"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1749875","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1749875"}}